Stemline Therapeutics (STML) Files $50M IPO
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Join SI Premium – FREE
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BOA Acquisition Corp. II prices $125 million IPO on Nasdaq
- Robinhood plans NYSE IPO for early-stage startup fund RVII
- East West Ave Acquisition Corp. closes $100M IPO on Nasdaq
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
